419 related articles for article (PubMed ID: 21591812)
1. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.
Agarwal A; Mackey MA; El-Sayed MA; Bellamkonda RV
ACS Nano; 2011 Jun; 5(6):4919-26. PubMed ID: 21591812
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting nanocarrier system based on thermosensitive liposomes and gold nanorods for cancer thermo-chemotherapy.
Yu M; Guo F; Tan F; Li N
J Control Release; 2015 Oct; 215():91-100. PubMed ID: 26256259
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Vile RG; Uster PS; Peters AM; Stewart JS
Clin Cancer Res; 2000 Dec; 6(12):4939-49. PubMed ID: 11156255
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Gupta B; Torchilin VP
Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.
Bandekar A; Karve S; Chang MY; Mu Q; Rotolo J; Sofou S
Biomaterials; 2012 Jun; 33(17):4345-52. PubMed ID: 22429980
[TBL] [Abstract][Full Text] [Related]
8. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
9. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
10. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
11. Gold cluster-labeled thermosensitive liposmes enhance triggered drug release in the tumor microenvironment by a photothermal effect.
Kwon HJ; Byeon Y; Jeon HN; Cho SH; Han HD; Shin BC
J Control Release; 2015 Oct; 216():132-9. PubMed ID: 26247553
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
[TBL] [Abstract][Full Text] [Related]
13. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure.
Frenkel V; Etherington A; Greene M; Quijano J; Xie J; Hunter F; Dromi S; Li KC
Acad Radiol; 2006 Apr; 13(4):469-79. PubMed ID: 16554227
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
16. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C
J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275
[TBL] [Abstract][Full Text] [Related]
17. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
[TBL] [Abstract][Full Text] [Related]
18. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
[TBL] [Abstract][Full Text] [Related]
19. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
20. Tumor priming enhances delivery and efficacy of nanomedicines.
Lu D; Wientjes MG; Lu Z; Au JL
J Pharmacol Exp Ther; 2007 Jul; 322(1):80-8. PubMed ID: 17420296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
